Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.60 USD
-0.09 (-5.33%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.60 USD
-0.09 (-5.33%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
UnitedHealth (UNH) Beats on Q4 Earnings, Retains 2023 View
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results gain from sustained membership growth in its UnitedHealthcare business.
Brookdale Senior Living (BKD) Q4 Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 14 straight months of year-over-year increases in weighted average occupancy level.
Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%
by Zacks Equity Research
Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 14.89% and 28.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Sotera Health Company (SHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -33.33% and 37.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LHC Group (LHCG) Q1 Earnings Surpass Estimates
by Zacks Equity Research
LHC (LHCG) delivered earnings and revenue surprises of 3.81% and 0.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Biodesix, Inc. (BDSX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) Q4 Earnings Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Q4 Loss Narrows on Higher Visits, Memberships
by Zacks Equity Research
Teladoc (TDOC) projects 2022 total visits in the band of 18.5-20 million, indicating an uptick from the 2021 level of 15.4 million.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 0.00% and 8.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.